Browsing Tag
vanoglipel
2 posts
Why MetaVia’s patent move may matter more than early weight loss data in the obesity market
MetaVia Inc. secures patent protection for its dual incretin obesity drug DA-1726 through 2041. Find out why this matters for investors and competitors.
MetaVia (NASDAQ: MTVA) raises $9.3m to advance DA-1726 after positive Phase 1b obesity data
MetaVia raised $9.3M to fund DA-1726 after strong obesity trial results. Find out how this dual-agonist strategy could reshape the GLP-1 landscape.